Press Release

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Feb. 1, 2023-- Veracyte, Inc. (Nasdaq: VCYT) today announced that six abstracts highlighting new data focused on the company’s Decipher urologic cancer testing offerings will be presented at the 2023 ASCO Genitourinary (GU) Cancers Symposium, taking place in San Francisco, Calif. and online, February 16-18, 2023.

Data being presented include new insights derived from Veracyte’s Decipher Genomics Resource for Intelligent Discovery (GRID) database, which suggest potential opportunities to further personalize treatment for men with prostate cancer. Additionally, researchers will present new Decipher Prostate Genomic Classifier clinical utility data from the prospective, phase 3, randomized clinical trial, G-MINOR (Genomics in Michigan ImpactiNg Observation or Radiation).

“Veracyte is committed to helping empower physicians with the insights they need to guide more informed, individualized treatment for patients with urologic cancers,” said Elai Davicioni, Ph.D., Veracyte’s medical director for Urology. “The data being presented at this year’s ASCO GU Cancers Symposium advance our understanding of how our Decipher genomic tests and Decipher GRID database may help physicians further stratify risk and guide treatment decisions for their patients with prostate or bladder cancer.”

Veracyte also expects additional data regarding the Decipher Prostate test to be highlighted in the following general session presentation:

Below are details of the abstracts that will be presented as posters at the 2023 ASCO GU Cancers Symposium in the Moscone Center in Moscone West, Level 1.

About Veracyte

Veracyte is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our high-performing tests enable clinicians to make more confident diagnostic, prognostic, and treatment decisions for some of the most challenging diseases such as thyroid, prostate, breast, bladder and lung cancers, as well as interstitial lung diseases. We help patients avoid unnecessary procedures and speed time to diagnosis and appropriate treatment. In addition to making our tests available in the U.S. through our central laboratories, our exclusive license to a best-in-class diagnostics instrument (the nCounter Analysis System) positions us to deliver our tests to patients worldwide through laboratories that can perform them locally. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to our statements related to our plans, objectives, expectations (financial and otherwise) or intentions with respect to our clinical tests in and outside of the United States. Forward-looking statements can be identified by words such as: “appears,” "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will," “positioned,” “designed” and similar references to future periods. Examples of forward-looking statements include, among others, how Veracyte’s Decipher Genomics Resource for Intelligent Discovery (GRID) database may help physicians further personalize treatment for men with prostate cancer and help physicians further stratify risk and guide treatment decisions for their patients with prostate or bladder cancer. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed on February 28, 2022, and our Quarterly Report on Form 10-Q to be filed for the three months ended September 30, 2022. Copies of these documents, when available, may be found in the Investors section of our website at www.investor.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.

Veracyte, the Veracyte logo and Decipher are registered trademarks of Veracyte, Inc. and its subsidiaries in the U.S. and selected countries. nCounter is the registered trademark of NanoString Technologies used by Veracyte under license.

Veracyte delivers the Decipher Prostate Genomic Classifier from its CLIA laboratories. Those tests are not CE-IVD marked and have not been cleared or approved by the FDA; their performance characteristics were determined by Veracyte and they might be considered for Research Use Only in some markets. Please contact Veracyte for confirmation. This piece is distributed purely for educational purposes and is not intended to promote or encourage any off-label use of Veracyte products.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230201005995/en/

Investors:
Shayla Gorman
Director, Investor Relations
investors@veracyte.com
619-393-1545

Media:
Tracy Morris
Vice President, Global Corporate Communications
tracy.morris@veracyte.com
650-380-4413

Source: Veracyte, Inc.